Crexendo Q2 2026: Revenue surges on M&A but per-share value erodes

What happened

Crexendo reported Q2 2026 revenue of $24.6 million, a 49% year-over-year increase, but the accompanying jump in diluted shares to approximately 36.7 million—a ~15% increase from Q3 2025—indicates that growth was primarily acquisition-driven and dilutive. GAAP net income of $1.1 million ($0.03 per share) fell substantially from $1.45 million ($0.048) in the prior quarter, as integration costs and the larger share count more than offset top-line expansion. The absence of segment detail in the press release obscures whether high-margin software solutions sustained their ~30% growth or whether the acquisition added lower-quality, lower-margin revenue. This outcome directly triggers the risk flagged in the master report: equity-funded M&A that increases share count by over 20% without clear per-share accretion, shifting the investment case from organic compounding to uncertain deal execution. The headline beat moves consolidated revenue toward the bull-case scenario but simultaneously raises the bar for proving that OCI cost savings and AI monetization can offset dilution and restore per-share earnings power.

Implication

Investors should treat the 49% top-line growth with caution, as the nearly 15% increase in share count and lower EPS indicate that the acquisition was dilutive per share, at least initially, while the lack of segment detail prevents a clear read on software momentum. If organic software growth has decelerated below 20% and those high-margin revenues are being diluted by lower-margin acquired services, the bull thesis is severely weakened. With shares around $7.00, the expanded market cap without commensurate earnings power stretches valuation further above the base-case $8 fair value. Management must now demonstrate that the acquisition can integrate to deliver at least $0.01–0.02 in incremental EPS within two quarters, alongside OCI margin lift and AI-driven ARPA uplift, to restore confidence in the capital-light compounding story. Until those catalysts materialize, the risk/reward profile has shifted less favorably, and we maintain a WAIT stance with a lowered attractive entry point, possibly below $5.50, reflecting dilution and integration uncertainty.

Thesis delta

The Q2 2026 report significantly alters the thesis by replacing organic 20%+ software-led growth with an acquisition-driven model that is currently dilutive per share. The prior base case of gradual AI monetization and OCI savings driving value toward $8–$10 is now challenged by a 15% jump in share count and declining quarterly EPS, requiring proof that the acquired assets and organic operations together can achieve the assumed ~$0.05+ quarterly EPS run-rate within 12 months to support valuation.